Jazzed Up for American Heart Association 2025 in New Orleans
Craig Beavers and Kyle Fischer, PharmD, BCCP, MBA, discuss key late-breaking cardiovascular trials expected at the American Heart Association’s upcoming annual meeting, exploring their clinical relevance and implications for pharmacists.
In this episode of The Tell-Tale Heart: The Pharmacist's Cardiovascular Digest, host Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP, speaks with Kyle Fischer, PharmD, BCCP, MBA, a cardiology clinical pharmacist at Ascension, about the late-breaking cardiovascular trials set to be presented at the upcoming American Heart Association Scientific Sessions.
Together, they preview several anticipated studies, discuss their potential impact on patient care, and reflect on how emerging data may shape clinical decision-making and pharmacist involvement in cardiovascular management. The conversation provides pharmacists with an engaging look ahead at the major themes and innovations likely to define this year’s AHA meeting.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Content
